Safety Profile

Discontinuations due to adverse reactions

During 1 year of treatment, discontinuations due to adverse reactions were reported by1:

  • 8.4% of patients taking placebo
  • 11.6% taking the starting dose (3.75 mg/23 mg)
  • 11.6% taking the recommended dose (7.5 mg/46 mg)
  • 17.4% taking the top dose (15 mg/92 mg)

Most common adverse reactions in patients for up to 1 year1

Most common adverse reactions (incidence ≥5% and at least 1.5 times placebo) are:

  • paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth1
    • Reports of paraesthesia were typically characterized as tingling in hands, feet, or face1

Choose Qsymia as first-line choice for a range of overweight and obese patient types who need to achieve significant weight loss1,2

Qsymia has been clinically proven to provide effective and well-tolerated treatment for a range of overweight and obese patient types1-2

Review Data by Patient Type